Details for Patent: 12,138,250
Which drugs does patent 12,138,250 protect, and when does it expire?
Patent 12,138,250 protects RETEVMO and is included in two NDAs.
Protection for RETEVMO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has twenty-four patent family members in fourteen countries.
Summary for Patent: 12,138,250
| Title: | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| Abstract: | 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed. |
| Inventor(s): | Mark Reynolds, Charles Todd Eary |
| Assignee: | Loxo Oncology Inc |
| Application Number: | US17/581,219 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 12,138,250
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Eli Lilly And Co | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Eli Lilly And Co | RETEVMO | selpercatinib | TABLET;ORAL | 218160-001 | Apr 10, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,138,250
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 113759 | ⤷ Start Trial | |||
| Australia | 2018347375 | ⤷ Start Trial | |||
| Brazil | 112020005368 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
